Expert Opinion on Investigational Drugs

Papers
(The H4-Index of Expert Opinion on Investigational Drugs is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL100
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy77
SGLT2 inhibitors: an evidence-based update on cardiovascular implications63
Theranostic strategies in sarcoma: preliminary clinical evidence51
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men46
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials40
Endoglin-targeted cancer therapies: current status and opportunities39
Current status and perspective of immunotherapy for head and neck squamous cell carcinoma39
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?36
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD36
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology32
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?29
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies26
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy26
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development25
Management of inflammaging in kidney diseases: focusing on the current investigational drugs25
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome25
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis24
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval24
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials23
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors23
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development23
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su22
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets22
0.64557504653931